| Twelves, Chris |
ELAINE 3, NCT05696626: Evaluation of Lasofoxifene Combined with Abemaciclib Compared with Fulvestrant Combined with Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer with an ESR1 Mutation |
|
|
| Recruiting | 3 | 400 | Europe, Canada, US, RoW | Lasofoxifene in combination with abemaciclib, Fulvestrant in combination with abemaciclib | Sermonix Pharmaceuticals Inc. | Metastatic Breast Cancer | 06/25 | 06/26 | | |
| Recruiting | 2 | 60 | Europe | Ixabepilone Injection | Allarity Therapeutics, Allarity Therapeutics | Metastatic Breast Cancer | 10/24 | 11/25 | | |
| Cook, Gordon |
| Recruiting | 3 | 740 | Europe | R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - reactive arm, Ninlaro, Revlimid, R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - adaptive arm, R2: Lenalidomide plus placebo maintenance, R2: Lenalidomide + ixazomib maintenance | University of Leeds, Cancer Research UK, Takeda, Celgene | Multiple Myeloma | 12/24 | 12/24 | | |
ACCoRd, NCT03562169: The Role of Ixazomib in Autologous Stem Cell Transplant in Relapsed Myeloma - Myeloma XII |
|
|
| Recruiting | 3 | 406 | Europe | Ixazomib, thalidomide, & dexamethasone (ITD) re-induction, Conventional autologous stem cell transplant (ASCT-con), Augmented autologous stem cell transplant (ASCT-aug), ITD consolidation and ixazomib maintenance vs. No further therapy | University of Leeds, Cancer Research UK, Takeda | Multiple Myeloma | 03/26 | 03/27 | | |
| Active, not recruiting | 1/2 | 336 | Europe, Canada, Japan, US, RoW | Modakafusp alfa, TAK-573, TEV-48573, Dexamethasone | Takeda | Multiple Myeloma | 02/24 | 11/24 | | |
| Completed | 1/2 | 15 | Europe, Canada, US, RoW | Modakafusp Alfa, TAK-573, Daratumumab | Takeda, Takeda Development Center Americas, Inc. | Multiple Myeloma | 05/24 | 05/24 | | |
| Completed | N/A | 1054 | Europe, RoW | | Stichting European Myeloma Network, Fondazione EMN Italy Onlus | Multiple Myeloma, Covid19, Corona Virus Infection | 08/22 | 03/24 | | |
| Minton, Jane |
NCT03696160: The Late Presenter Treatment Optimisation Study |
|
|
| Completed | 3 | 447 | Europe | Biktarvy, Symtuza | NEAT ID Foundation, Gilead Sciences, Janssen Pharmaceuticals | HIV/AIDS | 06/24 | 06/24 | | |
NCT01056185: Respiratory Virus Hospitalization Study (FLU 003 Plus) |
|
|
| Completed | N/A | 1000 | Europe, US, RoW | | University of Minnesota, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Clinical & Translational Science Institute, University of Minnesota | Influenza, Novel Respiratory Virus-1 Middle Eastern Respiratory Syndrome Coronavirus (MERS-CoV), Novel Respiratory Virus-2 Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) | 08/24 | 08/24 | | |
| Jayne, David |
| Active, not recruiting | 4 | 43 | Europe | Hydroxychloroquine, Plaquenil, Placebo, Control | Guy's and St Thomas' NHS Foundation Trust, Medical Research Council | ANCA Associated Vasculitis, Microscopic Polyangiitis, Churg-Strauss Syndrome, Wegener Granulomatosis | 05/25 | 05/25 | | |
OCEAN, NCT05263934 / 2021-005726-15: Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA) |
|
|
| Recruiting | 3 | 160 | Europe, Canada, Japan, US, RoW | Depemokimab, Mepolizumab, Placebo matching mepolizumab, Placebo matching depemokimab | GlaxoSmithKline | Eosinophilic Granulomatosis With Polyangiitis | 10/25 | 11/25 | | |
| Active, not recruiting | 2 | 18 | Europe | Rituximab, Infliximab, Tocilizumab | Cambridge University Hospitals NHS Foundation Trust | Giant Cell Arteritis, Takayasu Arteritis, Cogan Syndrome, Relapsing Polychondritis, Cryoglobulinemic Vasculitis, IgA Vasculitis, Polyarteritis Nodosa, Cutaneous Polyarteritis Nodosa, Primary Angiitis of Central Nervous System | 11/23 | 06/24 | | |
NCT03416023: Safety, Performance and Durability of the TIES® Implant in Patients Requiring a Permanent Ileostomy |
|
|
| Terminated | N/A | 28 | Europe | TIES® (Transcutaneous Implant Evacuation System) | Ostomycure AB, Veranex | Ileostomy - Stoma | 11/23 | 11/23 | | |
MASTERY, NCT04647188: Measuring the Quality of Surgical Care and Setting Benchmarks for Training Using Intuitive Data Recorder Technology |
|
|
| Active, not recruiting | N/A | 500 | Europe | Robotic assisted surgery with IDR data capture | University of Birmingham, Newcastle-upon-Tyne Hospitals NHS Trust, Imperial College Healthcare NHS Trust, Barts & The London NHS Trust, Portsmouth Hospitals NHS Trust, Royal Marsden NHS Foundation Trust, Wirral University Teaching Hospital NHS Trust, The Leeds Teaching Hospitals NHS Trust, Guy's and St Thomas' NHS Foundation Trust, South Tees Hospitals NHS Foundation Trust, University Hospitals Coventry and Warwickshire NHS Trust, Intuitive Surgical, University Hospitals, Leicester, Sheffield Teaching Hospitals NHS Foundation Trust, Golden Jubilee National Hospital, Royal Surrey County Hospital NHS Foundation Trust, Oxford University Hospitals NHS Trust, The Christie NHS Foundation Trust | Cancer, Surgery | 06/23 | 10/23 | | |
| Salama, Alan |
| Recruiting | 3 | 50 | Europe, US, RoW | Imlifidase, IdeS, HMED-IdeS, Plasma exchange (PLEX), PE, Cyclophosphamide (CYC), Glucocorticoids | Hansa Biopharma AB | Anti-Glomerular Basement Membrane Disease, Anti-Glomerular Basement Membrane Antibody Disease, Goodpasture Syndrome, Good Pasture Syndrome | 06/25 | 11/26 | | |
| Recruiting | 2/3 | 5000 | Europe | Niclosamide, Placebo, Ciclesonide, Sotrovimab | Cambridge University Hospitals NHS Foundation Trust, Life Arc, Kidney Research UK (KRUK), UNION therapeutics, Addenbrookes Charitable Trust, GlaxoSmithKline, National Institute for Health Research, United Kingdom | Covid19 | 07/24 | 12/24 | | |
NCT04699227: Can RIC Prevent Deterioration to Critical Care in Covid19 |
|
|
| Completed | N/A | 40 | Europe, RoW | Cuff application with inflation, Sham inflation | Derek Yellon | Covid19, Ischemia | 08/21 | 10/21 | | |
NCT04388930: The Microbiota in Kidney Donation and Transplantation |
|
|
| Recruiting | N/A | 130 | Europe | Pre-operative assessment - blood, urine, & faecal sample, Post-operative day 3 assessment - blood, urine, & faecal sample, Post-operative week 4-6 assessment - blood, urine, & faecal sample, Post-operative 3 month assessment - blood, urine, & faecal sample, Pre-operative 6 month assessment - blood, urine, & faecal sample, Post-operative month 12 recipient assessment - blood, urine, & faecal sample | Royal Free Hospital NHS Foundation Trust, University College, London | Kidney Diseases, Kidney Transplant Failure and Rejection, Urinary Tract Infections | 06/25 | 06/25 | | |
| Greenwood, John P |
| Completed | 2 | 49 | Europe | PROTHERACYTES, Standard Treatment for CHF post AMI | CellProthera | Acute Myocardial Infarction | 03/24 | 03/24 | | |
MicroRESUS, NCT05330676: Evaluation of Microcirculatory Function and Mitochondrial Respiration After Cardiovascular Surgery |
|
|
| Completed | N/A | 142 | US | coronary artery bypass grafting, valve repair/replacement | University of Pennsylvania, National Center for Advancing Translational Sciences (NCATS) | Shock, Cardiovascular Diseases, Critical Illness | 04/23 | 04/23 | | |
| Active, not recruiting | N/A | 807 | Europe | IVUS guided Percutaneous Coronary Intervention, QCA guided Percutaneous Coronary Intervention | ECRI bv, Philips Healthcare, Boston Scientific Corporation | Left Main Coronary Artery Stenosis | 07/25 | 07/25 | | |
BRITISH, NCT05568069: RCT of Implantable Defibrillators in Patients With Non Ischemic Cardiomyopathy, Scar and Severe Systolic Heart Failure |
|
|
| Recruiting | N/A | 2504 | Europe | Implantable Cardioverter-Defibrillator (ICD) or Cardiac Resynchronisation Therapy Defibrillator (CRTD) | University Hospital Southampton NHS Foundation Trust, British Heart Foundation, University of Southampton | Heart Failure | 04/26 | 04/36 | | |
| Recruiting | N/A | 2000 | Europe | Part 1: DCM Cohort, Whole genome sequencing and biomarker analysis, Part 2: Heritable CV Diseases and Family Members, Biomarker analysis | Imperial College London, British Heart Foundation, Royal Brompton & Harefield NHS Foundation Trust | Dilated Cardiomyopathy, Cardiovascular Diseases | 07/27 | 07/27 | | |
| Russell, David |
| Recruiting | 4 | 30 | US | Furosemide (plus potassium chloride), Placebo (plus placebo electrolyte solution) | Children's Hospital Medical Center, Cincinnati, Rainbow Babies and Children's Hospital, Emory University, RTI International, National Heart, Lung, and Blood Institute (NHLBI) | Bronchopulmonary Dysplasia | 09/25 | 09/25 | | |
| Active, not recruiting | 3 | 1667 | Japan, US | Remternetug (IV), LY3372993, Remternetug (SC), Placebo | Eli Lilly and Company | Alzheimer's Disease | 06/24 | 03/26 | | |
ENVISION, NCT05310071: A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease |
|
|
| Terminated | 3 | 1027 | Europe, Canada, Japan, US, RoW | Aducanumab, BIIB037, Aducanumab-avwa, Aduhelm, Placebo | Biogen | Alzheimer's Disease | 08/24 | 08/24 | | |
NCT05026866: A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3) |
|
|
| Active, not recruiting | 3 | 2196 | Japan, US | Donanemab, LY3002813, Placebo | Eli Lilly and Company | Alzheimer Disease | 11/27 | 11/27 | | |
| Completed | 2 | 23 | US | [18F] PI-2620 | Michael J. Fox Foundation for Parkinson's Research, Institute for Neurodegenerative Disorders | Parkinson Disease | 01/23 | 02/23 | | |
NCT00387075: A Study Evaluating Potential Screening Tools for Detecting Parkinson Disease |
|
|
| Active, not recruiting | 2 | 3000 | US | [123I]β-CIT and SPECT imaging, [123I]β-CIT | Institute for Neurodegenerative Disorders, United States Department of Defense, Molecular NeuroImaging | Parkinson Disease | 08/23 | 08/23 | | |
| Recruiting | 2 | 78 | Canada, US | Remote ischemic conditioning (RIC) + Standard of Care for NEC, Standard of Care for NEC | The Hospital for Sick Children, Thrasher Research Fund, Mount Sinai Hospital, Canada, Sunnybrook Health Sciences Centre, McMaster Children's Hospital, Children's Hospital Medical Center, Cincinnati, Children's Hospital of Orange County, Karolinska University Hospital, Sophia Kindergeneeskunde, UCL Great Ormond Street Institute of Child Health, Hospital Universitario La Paz, University of Southampton | Necrotizing Enterocolitis | 02/27 | 05/27 | | |
NCT04141150: Evaluation of [18F]APN-1607 PET Uptake in Alzheimer's Disease Patients Compared With Healthy Subjects |
|
|
| Active, not recruiting | 2 | 130 | US | [18F]APN-1607 | APRINOIA Therapeutics, LLC | Alzheimer's Disease, Mild Cognitive Impairment Due to Alzheimer's Disease, Healthy Volunteers | 09/24 | 02/25 | | |
LUMA, NCT05348785: A Study to Assess the Safety of BIIB122 Tablets and if it Can Slow the Worsening of Early-Stage Parkinson's Disease in Participants Between the Ages of 30 and 80 |
|
|
| Recruiting | 2 | 640 | Europe, Canada, Japan, US, RoW | BIIB122, DNL151, BIIB122-Matching Placebo | Biogen, Denali Therapeutics Inc. | Parkinson Disease | 12/25 | 12/25 | | |
NCT06445465: Study to Evaluate a Potential PET Radioligand for Imaging Alpha-synuclein Deposits in the Brain |
|
|
| Active, not recruiting | 1 | 30 | US | [18F]MNI-1216, [18F]ACI-12589 | Invicro, AC Immune SA | Alpha-Synucleinopathy, Parkinson's Disease, Dementia With Lewy Bodies, Multisystem Atrophy | 07/24 | 08/24 | | |
NCT05164536: Plasma P-tau2017 and Quantitative Amyloid PET Imaging |
|
|
| Recruiting | 1 | 200 | US | Amyvid, [18F]Florbetapir | Invicro | Alzheimer Disease | 09/22 | 09/22 | | |
| Completed | 1 | 10 | US | LY3857210 | Eli Lilly and Company | Healthy | 12/22 | 12/22 | | |
NCT05274568: Proof of Mechanism Study to Evaluate Binding of Alfa-synuclein |
|
|
| Recruiting | 1 | 14 | US | [18F]UCB-2897 | Invicro | Parkinson Disease, Multisystem Atrophy, Healthy Volunteer | 12/22 | 12/22 | | |
NCT05775601: 18F-LY3950321-01 Biodistribution and Safety Study |
|
|
| Completed | 1 | 6 | US | 18F-LY3950321, 18F-MNI-1256, PET Scan | Avid Radiopharmaceuticals | Diagnostic Agent Adverse Reaction, Radiation Exposure | 04/23 | 04/23 | | |
| Recruiting | 1 | 18 | US | [18F] APN-1607 | Invicro | Progressive Supranuclear Palsy, Healthy Volunteers | 06/24 | 06/24 | | |
| Active, not recruiting | N/A | 60 | Europe | | The Leeds Teaching Hospitals NHS Trust | Diabetic Foot, Diabetic Foot Ulcer | 04/24 | 04/24 | | |
NCT04507139: Early Longitudinal Imaging in Parkinson's Progression Markers Initiative Using [¹⁸F] AV-133 and DaTscan™ |
|
|
| Active, not recruiting | N/A | 50 | US | | Michael J. Fox Foundation for Parkinson's Research | Parkinson Disease | 06/25 | 06/25 | | |
| Recruiting | N/A | 4500 | Europe, Canada, US, RoW | | Michael J. Fox Foundation for Parkinson's Research, Institute for Neurodegenerative Disorders | Parkinson Disease | 12/33 | 12/33 | | |
| Investigator, Principal |
| Recruiting | 4 | 140 | Europe | Opicapone 50 mg, BIA 9-1067, Matching placebo | Bial - Portela C S.A., Bial - Portela & Ca, S.A. | Parkinson Disease | 12/22 | 12/22 | | |
NCT04248205: Ketamine for Post-operative Analgesia in Hemorrhoidectomy |
|
|
| Recruiting | 4 | 100 | US | Ketamine | University of Oklahoma | Hemorrhoids | 01/25 | 07/25 | | |
NCT05400369: A Study to Evaluate the Efficacy and Safety of Sitafloxacin in Adult Subjects With Acute Exacerbation of Chronic Obstructive Pulmonary Disease |
|
|
| Recruiting | 4 | 268 | RoW | Sitafloxacin, Gracevit, Moxifloxacin Hydrochloride, Avelox | Daiichi Sankyo | COPD Exacerbation Acute | 09/24 | 12/24 | | |
TrEAT_TD2, NCT05677282: Single Dose Antibiotic Treatment of Acute Watery Diarrhea, Rifaximin Versus Azithromycin, With Loperamide Adjunct |
|
|
| Recruiting | 4 | 150 | RoW | Rifaximin 550 MG, Azithromycin 500 MG, Loperamide | Henry M. Jackson Foundation for the Advancement of Military Medicine, Infectious Diseases Clinical Research Program, Uniformed Services University of the Health Sciences | Diarrhoea;Acute, Diarrhea Travelers | 06/25 | 09/25 | | |
NCT06397781: Effect of S. Aureus Skin Decolonization on Disease Severity in Atopic Dermatitis Patients |
|
|
| Not yet recruiting | 4 | 100 | US | Skin Cleanser Combination No.1 | Boston Children's Hospital | Atopic Dermatitis | 12/28 | 12/28 | | |
POUR, NCT04994431: Post-Operative Urinary Retention () in Thoracic Surgery Patients Receiving Prophylactic Tamsulosin |
|
|
| Terminated | 4 | 109 | US | Tamsulosin Hydrochloride | University of Massachusetts, Worcester, UMass Memorial Health Care | Thoracic Diseases, Urinary Retention | 10/23 | 10/23 | | |
NCT02932410 / 2016-001062-28: A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH) |
|
|
| Active, not recruiting | 3 | 165 | Europe, Canada, US, RoW | Macitentan, ACT-064992, Standard-of-care | Actelion | Pulmonary Arterial Hypertension | 11/23 | 12/24 | | |
| Active, not recruiting | 3 | 590 | Europe, Canada, Japan, US, RoW | DS-1062a, Datopotamab deruxtecan (Dato-DXd), Docetaxel | Daiichi Sankyo, AstraZeneca | Non-small Cell Lung Cancer | 05/24 | 06/25 | | |
|
|
IDeate-Lung02, NCT06203210: A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer |
|
|
| Recruiting | 3 | 540 | Europe, Canada, Japan, US, RoW | Ifinatamab deruxtecan, I-DXd, Topotecan, Amrubicin, Lurbinectedin | Daiichi Sankyo, Merck Sharp & Dohme LLC | Small Cell Lung Cancer | 04/27 | 02/29 | | |
TNX-N, NCT03503136: Nedaplatin Versus Cisplatin and Capecitabine Versus Fluorouracil in IC + CCRT for Locoregionally Advanced NPC |
|
|
| Not yet recruiting | 3 | 632 | RoW | docetaxel, nedaplatin, and capecitabine, TNX induction chemotherapy, nedaplatin, N, docetaxel, cisplatin, and fluorouracil, TPF induction chemotherapy, cisplatin, P, docetaxel, cisplatin, and capecitabine, TPX induction chemotherapy, docetaxel, nedaplatin, and fluorouracil, TNF induction chemotherapy | Sun Yat-sen University, Tongji Hospital, Wuhan Union Hospital, China, Peking University, Air Force Military Medical University, China, Second Affiliated Hospital of Soochow University, The First Affiliated Hospital of Guangdong Pharmaceutical University, First People's Hospital of Foshan, Fifth Affiliated Hospital, Sun Yat-Sen University, Cancer Hospital of Guizhou Province, Xiangya Hospital of Central South University, Jilin Provincial Tumor Hospital, Henan Cancer Hospital, Hunan Cancer Hospital, Cancer Hospital of Guangxi Medical University, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Zhejiang Cancer Hospital | Nasopharyngeal Carcinoma | 06/24 | 06/26 | | |
NCT05839899: Mifepristone and Misoprostol for Undesired Pregnancy of Unknown Location |
|
|
| Recruiting | 3 | 50 | US | Mifepristone plus one dose Misoprostol, Mifepristone plus two doses Misoprostol | Planned Parenthood League of Massachusetts | Abortion | 07/24 | 09/24 | | |
| Active, not recruiting | 3 | 586 | Europe, Canada, Japan, US, RoW | Patritumab Deruxtecan, HER3-DXd, U3-1402, Platinum-based chemotherapy | Daiichi Sankyo, Merck Sharp & Dohme LLC | Nonsquamous Non-small Cell Lung Cancer, EGFR L858R, EGFR Exon 19 Deletion | 05/24 | 06/26 | | |
CYPRESS, NCT05696717: Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic NOH in Participants with Multiple System Atrophy |
|
|
| Recruiting | 3 | 102 | Europe, Canada, US, RoW | Ampreloxetine, TD-9855, Placebo | Theravance Biopharma | Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy | 12/24 | 01/27 | | |
NCT06672016: Study to Evaluate Contraceptive Efficacy and Safety of a Progestin Only Patch in Women of Childbearing Potential |
|
|
| Not yet recruiting | 3 | 1500 | US | Transdermal system containing progestin | Mylan Pharmaceuticals Inc | Female Contraception | 03/27 | 04/27 | | |
| Active, not recruiting | 3 | 899 | Europe, Canada, Japan, US, RoW | Tafasitamab, Monjuvi, Lenalidomide, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Tafasitamab placebo, Lenalidomide placebo | Incyte Corporation | Diffuse Large B-cell Lymphoma | 06/25 | 05/26 | | |
|
|
|
| Completed | 3 | 1 | US | StrataGraft | Stratatech, a Mallinckrodt Company, Biomedical Advanced Research and Development Authority | Skin Wound, Burns, Trauma-related Wound | 05/24 | 05/24 | | |
| Active, not recruiting | 3 | 490 | Europe, Japan, RoW | Trastuzumab deruxtecan, T-DXd, DS-8201a, ENHERTU®, Ramucirumab, CYRAMZA®, Paclitaxel | Daiichi Sankyo, AstraZeneca | Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | 10/25 | 02/26 | | |
|
|
|
|
NCT05847348: 68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese Patients |
|
|
| Recruiting | 3 | 110 | RoW | 68Ga-PSMA-11, Illucix, gallium Ga 68 Gozetotide, PET/CT or PET/MRI, Imaging by PET | Telix Pharmaceuticals (Innovations) Pty Limited, Grand Pharmaceutical (China) Co., Ltd. | Biochemical Recurrence of Malignant Neoplasm of Prostate, Prostate Cancer, BCR Prostate Carcinoma | 12/25 | 07/26 | | |
| Active, not recruiting | 3 | 1600 | Europe, Canada, Japan, US, RoW | DS-8201a, Trastuzumab deruxtecan (T-DXd), T-DM1, Trastuzumab emtansine (T-DM1) | Daiichi Sankyo, AstraZeneca, NSABP Foundation Inc, German Breast Group, Spanish Breast Cancer Research Group (SOLTI) | HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer | 12/25 | 12/30 | | |
|
|
FREEDOM, NCT05817812: A Study Evaluating Physical Activity and Joint Health in Severe Haemophilia A Patients ≥12 Years Treated Once Weekly With Efanesoctocog Alfa |
|
|
| Active, not recruiting | 3 | 93 | Europe, RoW | Efanesoctocog alfa, BIVV001 | Swedish Orphan Biovitrum, Syneos Health | Hemophilia A, Severe | 05/26 | 05/26 | | |
TROPION-Lung07, NCT05555732: Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer |
|
|
| Recruiting | 3 | 1170 | Europe, Canada, Japan, US, RoW | Datopotamab Deruxtecan, Dato-DXd, Pembrolizumab, KEYTRUDA®, Pemetrexed, Alimta, Pemfexy, Carboplatin, Cisplatin | Daiichi Sankyo, AstraZeneca, Merck Sharp & Dohme LLC | Metastatic Non Small Cell Lung Cancer | 08/27 | 08/27 | | |
DESTINY-Breast15, NCT05950945: Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer |
|
|
| Recruiting | 3 | 250 | Europe, US, RoW | Trastuzumab Deruxtecan, T-DXd, DS-8201a (trastuzumab derextecan), Enhertu® | Daiichi Sankyo, AstraZeneca | Breast Cancer | 10/27 | 10/27 | | |
| Recruiting | 3 | 740 | Europe, Canada, Japan, US, RoW | Datopotamab Deruxtecan, Dato-DXd, Pembrolizumab, KEYTRUDA® | Daiichi Sankyo, AstraZeneca, Merck Sharp & Dohme LLC | Metastatic Non Small Cell Lung Cancer | 02/28 | 04/28 | | |
|
|
ARTEMIS, NCT04797884: Electromagnetic Fields Versus Placebo For Child-Pugh A and B Patients With Advanced Hepatocellular Carcinoma |
|
|
| Recruiting | 2/3 | 166 | US | TheraBionic Device, Placebo Device, Quality of Life Assessment | THERABIONIC INC., National Cancer Institute (NCI) | Hepatocellular Carcinoma | 10/24 | 10/24 | | |
TRIPHASE, NCT06101745: Trial to Visualize the Ureters With Nizaracianine Triflutate in Adults Undergoing Abdominopelvic Surgery |
|
|
| Recruiting | 2/3 | 336 | Europe | Nizaracianine Triflutate, ZW800-1, Placebo Comparator, Sugar | Curadel Surgical Innovations, Inc., Leiden University Medical Center, Erasmus Medical Center | Injury of Ureter During Surgery (Disorder) | 10/25 | 11/25 | | |
| Terminated | 2 | 16 | Europe, Canada, US, RoW | Belcesiran, Placebo | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | Alpha 1-Antitrypsin Deficiency | 12/23 | 05/24 | | |
AAVIATE, NCT04514653: RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD) |
|
|
| Recruiting | 2 | 115 | US | Ranibizumab, RGX-314 Dose 1, Combination Product, RGX-314 Dose 2, RGX-314 Dose 3, Local Steroid, Topical Steroid | AbbVie, AbbVie | Neovascular Age-Related Macular Degeneration (nAMD) | 10/25 | 08/26 | | |
| Completed | 2 | 60 | US | RGX-314 | AbbVie | Neovascular Age-related Macular Degeneration, Wet Macular Degeneration, Wet Age-related Macular Degeneration | 10/23 | 03/24 | | |
Orchid 1, NCT06132919: Efficacy and Safety of MC2-25 Cream & Vehicle in Women With Vulvar Lichen Sclerosus (VLS) |
|
|
| Recruiting | 2 | 40 | Europe | MC2-25 cream, MC2-25 vehicle | MC2 Therapeutics | Vulvar Lichen Sclerosus | 11/24 | 11/24 | | |
| Completed | 2 | 13 | US | AG Tx, Meshed Autograft, SOMA Tx, StrataGraft skin tissue Overlay of Meshed Autograft (SOMA) | Stratatech, a Mallinckrodt Company | Full Thickness Thermal Burn | 03/24 | 03/24 | | |
| Recruiting | 2 | 400 | Japan, US, RoW | HER3-DXd, Patritumab Deruxtecan, U3-1402 | Daiichi Sankyo, Merck Sharp & Dohme LLC | Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer, Ovarian Carcinoma, Cervical Cancer, Endometrial Cancer, Bladder Cancer, Esophageal Cancer, Pancreatic Carcinoma, Prostate Cancer | 06/25 | 04/26 | | |
NCT05198310: Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase Inhibitor |
|
|
| Completed | 2 | 145 | Europe, US, RoW | KPL-404, Placebo | Kiniksa Pharmaceuticals, Ltd. | Arthritis, Rheumatoid | 02/24 | 05/24 | | |
EAD501, NCT05607615: A 6-Month Study to Evaluate the Safety & Potential Efficacy of Trappsol Cyclo in Patients With Early Alzheimer's Disease |
|
|
| Recruiting | 2 | 90 | US | Hydroxypropyl Beta Cyclodextrin, Trappsol Cyclo, Placebo, 0.5N saline | Cyclo Therapeutics, Inc. | Alzheimer's Disease | 03/24 | 03/24 | | |
| Completed | 2 | 64 | Europe, US | DS-1211b, Placebo | Daiichi Sankyo, PXE International | Pseudoxanthoma Elasticum | 11/23 | 11/23 | | |
MAST, NCT06355583: Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant () Trial |
|
|
| Not yet recruiting | 2 | 50 | Europe | EBX-102, IMT capsules, Placebo | Imperial College London | Acute Lymphoblastic Leukaemia, Acute Leukemia of Ambiguous Lineage, Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Acute Myeloid Leukemia | 02/26 | 05/27 | | |
NCT04870905: Tisleilizumab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma |
|
|
| Not yet recruiting | 2 | 100 | RoW | Tis-U-Sol | Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Union hospital of Fujian Medical University, Zhujiang Hospital, Guangdong Provincial People's Hospital | Nasopharyngeal Neoplasms | 05/24 | 05/26 | | |
| Active, not recruiting | 2 | 187 | Europe, Japan, US, RoW | Ifinatamab Deruxtecan (I-DXd), DS-7300a | Daiichi Sankyo, Merck Sharp & Dohme LLC | Extensive-stage Small-cell Lung Cancer | 01/25 | 04/25 | | |
| Recruiting | 2 | 32 | RoW | SPG302, Placebo | Spinogenix | Schizophrenia | 06/25 | 10/25 | | |
CBeyond, NCT06577090: Study to Evaluate the Effect on Obesity of Once Weekly Nimacimab Injection and Once Weekly Nimacimab Injection Co-administered With Semaglutide Injection Versus Placebo |
|
|
| Recruiting | 2 | 120 | US | Nimacimab injection, Nimacimab placebo injection, semaglutide injection | Skye Bioscience, Inc., Bird Rock Bio Sub, Inc. | Obesity | 08/25 | 01/26 | | |
NCT05029336: Autologous Stem Cell Transplant (ASCT) for Autoimmune Diseases |
|
|
| Recruiting | 2 | 20 | US | Depletion of CD3/CD19 in an autologous stem cell transplant, CD3/CD19 depletion using cliniMACs device | Stephan Grupp MD PhD | Systemic Lupus Erythematosus, Systemic Sclerosis | 12/26 | 05/31 | | |
| Recruiting | 2 | 64 | US | Bevonescein, ALM-488 | Alume Biosciences, Inc. | Surgery, Nerve Injury, Imaging | 06/25 | 09/25 | | |
NCT04935762: A Study of CST-103 Co-administered With CST-107 in Subjects With Parkinson's Disease Having Freezing of Gait (CLIN-012) |
|
|
| Withdrawn | 2 | 25 | RoW | CST-103, CST-107, matching placebo | CuraSen Therapeutics, Inc. | Freezing of Gait Symptoms in Parkinson's Disease | 12/24 | 03/25 | | |
| Not yet recruiting | 2 | 200 | US | Raludotatug deruxtecan, R-DXd | Daiichi Sankyo, Merck Sharp & Dohme LLC | Advanced Solid Tumor, Metastatic Solid Tumors | 09/27 | 09/27 | | |
NCT04977024: SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer |
|
|
| Recruiting | 2 | 240 | US | COVID-19 Vaccine, Diagnostic Laboratory Biomarker Analysis, Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1, COH04S1, SARS-CoV-2 Vaccine COH04S1, sMVA-based SARS-CoV-2 Vaccine COH04S1, GEO-CM04S1 | GeoVax, Inc., National Cancer Institute (NCI) | COVID-19 Infection, Hematopoietic and Lymphoid System Neoplasm, Leukemia, Lymphoma, Plasma Cell Myeloma | 03/25 | 03/26 | | |
STEP, NCT06594393: A Phase 2 Study of TCP-25 Gel in Patients with Epidermolysis Bullosa, -study |
|
|
| Not yet recruiting | 2 | 26 | Europe | TCP-25 gel, Vehicle (placebo) | Xinnate AB | Epidermolysis Bullosa (EB) | 06/26 | 06/26 | | |
NCT06038578: A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer |
|
|
| Recruiting | 2 | 146 | Japan, US, RoW | TRK-950, Ramucirumab, CYRAMZA®, Paclitaxel | Toray Industries, Inc | Gastric Adenocarcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | 08/25 | 08/25 | | |
NCT05205330: CR6086/AGEN2034 Combination in Stage IV pMMR - MSS CRC, and Other Metastatic GI Cancers |
|
|
| Recruiting | 1/2 | 55 | Europe | CR6086, vorbipiprant, AGEN2034, balstilimab | Rottapharm Biotech, Agenus Inc. | Refractory Metastatic Colorectal Cancer, Solid Tumor, Metastatic Microsatellite-stable Colorectal Cancer, Mismatch Repair Protein Proficient, Metastatic GI Cancers, Gastric Cancer | 03/25 | 09/26 | | |
NCT05638802: A Study of DS-7011a in Patients With Systemic Lupus Erythematosus |
|
|
| Active, not recruiting | 1/2 | 26 | US | DS-7011a, Placebo | Daiichi Sankyo | Systemic Lupus Erythematosus | 04/25 | 04/25 | | |
| Active, not recruiting | 1/2 | 190 | Europe, US | ASTX029 | Taiho Oncology, Inc. | Solid Tumor, Adult | 04/24 | 12/25 | | |
NCT05979831: A Study to Explore Safety, Pharmacokinetics, and Early Clinical Signal of Efficacy of DS-2325a in Patients With Netherton Syndrome |
|
|
| Active, not recruiting | 1/2 | 9 | Europe | DS-2325a, Placebo | Daiichi Sankyo | Netherton Syndrome | 01/25 | 01/25 | | |
IDeate-Lung03, NCT06362252: A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer |
|
|
| Recruiting | 1/2 | 123 | Europe, Japan, US | Ifinatamab deruxtecan, I-DXd, Atezolizumab, Carboplatin | Daiichi Sankyo, Merck Sharp & Dohme LLC | Extensive Stage-small Cell Lung Cancer | 09/26 | 12/26 | | |
| Recruiting | 1/2 | 145 | US, RoW | SQ3370 | Shasqi, Inc. | Cancer | 08/24 | 07/26 | | |
| Recruiting | 1/2 | 250 | Japan, US | Ifinatamab deruxtecan (I-DXd) | Daiichi Sankyo, Merck Sharp & Dohme LLC | Advanced Solid Tumor, Malignant Solid Tumor | 12/25 | 03/27 | | |
|
| Active, not recruiting | 1/2 | 666 | Europe, Canada, US, RoW | Epcoritamab, GEN3013, DuoBody®-CD3xCD20, EPKINLY™ | Genmab, AbbVie | DLBCL, High-grade B-cell Lymphoma (HGBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL), FL, MCL, Small Lymphocytic Lymphoma (SLL), Marginal Zone Lymphoma (MZL) | 03/25 | 01/29 | | |
|
|
|
|
|
|
|
|
|
|
|
NCT05693025: Evaluation of the Walk With Ease Program for Fall Prevention |
|
|
| Recruiting | 1/2 | 240 | US | Group Exercise, Behavioral Training | Iowa State University | Exercise, Frailty, Arthritis, Accidental Falls | 05/25 | 05/26 | | |
| Recruiting | 1/2 | 430 | Europe, Japan, US | DS-3939a | Daiichi Sankyo | Advanced Solid Tumor, Metastatic Solid Tumor | 03/26 | 07/27 | | |
NCT03793478 / 2016-002919-18: Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood |
|
|
| Active, not recruiting | 1/2 | 65 | Europe, Canada, US, RoW | Quizartinib, Quizartinib dihydrochloride, Vanflyta, Fludarabine, Cytarabine, Intrathecal (IT) triple chemotherapy prophylaxis, Etoposide | Daiichi Sankyo, Innovative Therapies For Children with Cancer Consortium, Children's Oncology Group | Acute Myeloid Leukemia | 05/27 | 05/27 | | |
| Recruiting | 1 | 309 | Europe, Japan, US, RoW | HER3-DXd (FL-DP), HER3-DXd (CTM-1 Lyo-DP), HER3-DXd (CTM-3 Lyo-DP) | Daiichi Sankyo, Merck Sharp & Dohme LLC | Non-Small Cell Lung Cancer (NSCLC) | 03/26 | 12/26 | | |
|
|
NCT05203692: A Study of a Single Ascending Dose Study of DS-7011a in Healthy Subjects |
|
|
| Completed | 1 | 80 | US | DS-7011a, Placebo | Daiichi Sankyo, Inc. | Systemic Lupus Erythematosus | 01/23 | 03/23 | | |
